(Q36561051)

14 August 2017

1 reference

title

Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence (English)

1 reference

14 August 2017

1 reference

Michelle Orme

1

1 reference

14 August 2017

Annabel Boler

series ordinal

2

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

743-750

1 reference

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624080-00002

Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00019053-200624080-00002

A Markov modelled pharmacoeconomic analysis of bimatoprost 0.03% in the treatment of glaucoma as an alternative to filtration surgery in Italy

21 January 2018

1 reference

12 December 2020

A cost analysis of the prostaglandin analogs.

1 reference

12 December 2020

A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany.

1 reference

12 December 2020

Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 1 year.

1 reference

12 December 2020

An economic analysis of switching to latanoprost from a beta-blocker or adding brimonidine or latanoprost to a beta-blocker in open-angle glaucoma or ocular hypertension.

1 reference

12 December 2020

1 reference

12 December 2020

Refill rates and budget impact of glaucoma lipid therapy: a retrospective database analysis

1 reference

12 December 2020

Cost analysis of glaucoma medications: a 3-year review

1 reference

12 December 2020

A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension

1 reference

12 December 2020

Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France

1 reference

12 December 2020

Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head.

1 reference

12 December 2020

Medical therapy cost considerations for glaucoma

1 reference

12 December 2020

Daily cost of ophthalmic solutions for treating glaucoma in Japan

1 reference

12 December 2020

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

1 reference

12 December 2020

Modeling cost of treatment with new topical treatments for glaucoma. Results from France and the United Kingdom.

1 reference

12 December 2020

Best practice treatment algorithm for primary open-angle glaucoma: implications for U.S. ophthalmology practice

1 reference

12 December 2020

10.2165/00019053-200624080-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1005380566

0 references

1 reference